Diametric Capital LP Takes Position in Sanofi (NASDAQ:SNY)

Diametric Capital LP acquired a new position in Sanofi (NASDAQ:SNY) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 4,444 shares of the company’s stock, valued at approximately $214,000.

Other hedge funds have also bought and sold shares of the company. Synergy Asset Management LLC purchased a new position in shares of Sanofi in the 4th quarter worth $25,000. McClarren Financial Advisors Inc. boosted its position in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in Sanofi in the fourth quarter worth about $31,000. Sunbelt Securities Inc. increased its position in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the last quarter. Finally, Sierra Ocean LLC purchased a new stake in shares of Sanofi during the 4th quarter valued at about $44,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Down 0.7 %

Shares of SNY stock opened at $53.95 on Thursday. The company has a market capitalization of $136.92 billion, a price-to-earnings ratio of 21.67, a PEG ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company’s fifty day moving average price is $55.33 and its 200-day moving average price is $52.74. Sanofi has a one year low of $45.22 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SNY. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target for the company. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.